Latest Rilpivirine Stories
New long-acting formulations may improve adherence and increase uptake; add an important tool to the portfolio of prevention interventions South San Francisco,
Agreement is ViiV Healthcare's first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine LONDON, June 12, 2014 /PRNewswire/ -- ViiV Healthcare
TITUSVILLE, N.J., July 19, 2011 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor (NNRTI) EDURANT(TM) (rilpivirine) tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.
TITUSVILLE, N.J., May 20, 2011 /PRNewswire/ -- The US Food and Drug Administration (FDA) today approved EDURANT(TM) (rilpivirine) tablets for use in combination with other antiretroviral agents (ARVs) in the treatment of human immunodeficiency virus type 1 (HIV-1) in adults who have never taken HIV therapy (treatment-naive).
CORK, Ireland, Jan.
BURLINGTON, Mass., Oct.
CORK, Ireland, September 3, 2010 /PRNewswire/ -- Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV.
TITUSVILLE, N.J., July 26 /PRNewswire/ -- Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S.
- A bereavement by loss of parents or children; the state of being orbate; orbation.